B
Bull
Bull · 25%ANRO
$3.25
Precio del escenario
$35.130
-1.131 (-3.22%)Al cierre
Loading chart…
- High
- 35.720
- Open
- 35.000
- VWAP
- 35.19
- Vol
- 246.76K
- Mkt Cap
- —
- Low
- 34.730
- Amount
- 8.68M
- EV/EBITDA, TTM
- 0.00
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
AI analysis of Alto Neuroscience Inc (ANRO)
buyAlto Neuroscience Inc is a good buy right now at a current price of $35.13. The stock has shown strong momentum with a year-to-date change of +111.75% and a 1-year change of +805.41%. Additionally, the RSI is at 58.57, indicating bullish momentum. However, the main risk is the widening net losses, which reached -$27.6 million in Q2 2026, suggesting ongoing financial challenges.
Métricas de valoración
The current forward P/E ratio for Alto Neuroscience Inc (ANRO) is 0.00, compared to its 5-year average forward P/E of -3.24.
Alphio AI Price Scenarios for ANRO
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ANRO
Cronología de eventos
Noticias
7.508-13NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Positive Catalysts
7.508-07NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Key Catalysts
8.507-15NASDAQ.COMAlto Neuroscience Completes $100 Million Financing
8.507-15NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Key Catalysts
8.505-15NewsfilterAlto Neuroscience CEO Amit Etkin Receives Transformational Research Award
ANRO FAQ — answered by Alphio AI
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Alto Neuroscience Inc is a good buy right now at a current price of $35.13. The stock has shown strong momentum with a year-to-date change of +111.75% and a 1-year change of +805.41%. Additionally, the RSI is at 58.57, indicating bullish momentum. However, the main risk is the widening net losses, which reached -$27.6 million in Q2 2026, suggesting ongoing financial challenges.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.